BACKGROUND: Bone marrow-derived endothelial progenitor cells (EPCs) are critical for metastatic progression. This study explores the effect of tetrathiomolybdate (TM), an anti-angiogenic copper chelator, on EPCs in patients at high risk for breast cancer recurrence. PATIENTS AND METHODS: This phase 2 study enrolled breast cancer patients with stage 3 and stage 4 without evidence of disease (NED), and stage 2 if triple-negative. TM 100 mg orally was administered to maintain ceruloplasmin <17 mg/dl for 2 years or until relapse. The primary end point was change in EPCs. RESULTS: Forty patients (28 stage 2/3, 12 stage 4 NED) were enrolled. Seventy-five percent patients achieved the copper depletion target by 1 month. Ninety-one percent of triple-negative patients copper-depleted compared with 41% luminal subtypes. In copper-depleted patients only, there was a significant reduction in EPCs/ml by 27 (P = 0.04). Six patients relapsed while on study, of which only one patient had EPCs maintained below baseline. The 10-month relapse-free survival was 85.0% (95% CI 74.6%-96.8%). Only grade 3/4 toxicity was hematologic: neutropenia (3.1% of cycles), febrile neutropenia (0.2%), and anemia (0.2%). CONCLUSIONS: TM is safe and appears to maintain EPCs below baseline in copper-depleted patients. TM may promote tumor dormancy and ultimately prevent relapse.
BACKGROUND: Bone marrow-derived endothelial progenitor cells (EPCs) are critical for metastatic progression. This study explores the effect of tetrathiomolybdate (TM), an anti-angiogenic copper chelator, on EPCs in patients at high risk for breast cancer recurrence. PATIENTS AND METHODS: This phase 2 study enrolled breast cancerpatients with stage 3 and stage 4 without evidence of disease (NED), and stage 2 if triple-negative. TM 100 mg orally was administered to maintain ceruloplasmin <17 mg/dl for 2 years or until relapse. The primary end point was change in EPCs. RESULTS: Forty patients (28 stage 2/3, 12 stage 4 NED) were enrolled. Seventy-five percent patients achieved the copper depletion target by 1 month. Ninety-one percent of triple-negative patientscopper-depleted compared with 41% luminal subtypes. In copper-depleted patients only, there was a significant reduction in EPCs/ml by 27 (P = 0.04). Six patients relapsed while on study, of which only one patient had EPCs maintained below baseline. The 10-month relapse-free survival was 85.0% (95% CI 74.6%-96.8%). Only grade 3/4 toxicity was hematologic: neutropenia (3.1% of cycles), febrile neutropenia (0.2%), and anemia (0.2%). CONCLUSIONS:TM is safe and appears to maintain EPCs below baseline in copper-depleted patients. TM may promote tumor dormancy and ultimately prevent relapse.
Entities:
Keywords:
breast cancer; endothelial progenitor cells; tetrathiomolybdate
Authors: Bruce G Redman; Peg Esper; Quintin Pan; Rodney L Dunn; Hero K Hussain; Thomas Chenevert; George J Brewer; Sofia D Merajver Journal: Clin Cancer Res Date: 2003-05 Impact factor: 12.531
Authors: Quintin Pan; Celina G Kleer; Kenneth L van Golen; Jennifer Irani; Kristen M Bottema; Carlos Bias; Magda De Carvalho; Enrique A Mesri; Diane M Robins; Robert D Dick; George J Brewer; Sofia D Merajver Journal: Cancer Res Date: 2002-09-01 Impact factor: 12.701
Authors: Roland N Dickerson; Vanessa J Kumpf; Carol J Rollins; Eric H Frankel; Michael D Kraft; Todd W Canada; Catherine M Crill Journal: Hosp Pharm Date: 2014-09
Authors: Anna Członkowska; Tomasz Litwin; Petr Dusek; Peter Ferenci; Svetlana Lutsenko; Valentina Medici; Janusz K Rybakowski; Karl Heinz Weiss; Michael L Schilsky Journal: Nat Rev Dis Primers Date: 2018-09-06 Impact factor: 52.329
Authors: Kristin M Bompiani; Cheng-Yu Tsai; Felix P Achatz; Janika K Liebig; Stephen B Howell Journal: Metallomics Date: 2016-05-09 Impact factor: 4.526
Authors: Monika Krawczyk; Gabriela Pastuch-Gawołek; Aleksandra Pluta; Karol Erfurt; Adrian Domiński; Piotr Kurcok Journal: Molecules Date: 2019-11-18 Impact factor: 4.411